Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
BioProcess Internation...BioProcess International US West
Not Confirmed
Not Confirmed
09-11 March, 2026
BioProcess Internation...BioProcess International
Not Confirmed
Not Confirmed
09-11 March, 2026
Not Confirmed
Not Confirmed
09-11 March, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
BioProcess International US West
Not Confirmed
Contact SupplierBioProcess International US West
BioProcess Internation...BioProcess International US West
Industry Trade Show
Not Confirmed
09-11 March, 2026
BioProcess Internation...BioProcess International
Industry Trade Show
Not Confirmed
09-11 March, 2026
Industry Trade Show
Not Confirmed
09-11 March, 2026
Digital content
NEWS #PharmaBuzz
09 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/09/3058128/0/en/ValoTx-Appoints-Marcella-Origgi-from-Johnson-Johnson-Innovation-as-CEO.html
10 Mar 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/03/10/3039464/0/en/Valo-Therapeutics-announces-EUR-19m-of-investment-funding-and-expanded-clinical-trials.html
06 Nov 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/11/06/2975782/18623/en/Lisata-Therapeutics-and-Valo-Therapeutics-Announce-Preclinical-Research-Collaboration.html
29 Nov 2023
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2023/11/29/2787495/0/en/Valo-Therapeutics-Announces-Regulatory-Approval-to-Expand-Phase-I-Immuno-oncology-Trial-into-Sarcoma.html
10 Oct 2023
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2023/10/10/2757151/0/en/Valo-Therapeutics-Announces-Acquisition-of-Bruker-Corporation-s-Latest-Mass-Spectrometer-Platform-for-Tumor-Antigen-Identification-with-ValoTx-s-PeptiCHIP-Technology.html
15 Jun 2023
// PHARMABIZ
Drugs in Development
Details:
The financing will enable Valo to expand and complete the Phase 1B clinical study of PeptiCRAd-1, the company's lead tumour antigen-coated oncolytic virus candidate.
Lead Product(s): PeptiCRAd-1,Cyclophosphamide,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Vaccine
Sponsor: Indaco Venture Partners
Deal Size: $20.6 million Upfront Cash: Undisclosed
Deal Type: Financing March 10, 2025
Lead Product(s) : PeptiCRAd-1,Cyclophosphamide,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Indaco Venture Partners
Deal Size : $20.6 million
Deal Type : Financing
Valo Therapeutics Announces EUR 19m of Investment Funding and Expanded Clinical Trials
Details : The financing will enable Valo to expand and complete the Phase 1B clinical study of PeptiCRAd-1, the company's lead tumour antigen-coated oncolytic virus candidate.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
March 10, 2025
Details:
The collaboration aims to investigate the benefits of combining Lisata's, LSTA1 (certepetide), with ValoTx's platform technology, PeptiCRAd, and a checkpoint inhibitor in a melanoma mouse model.
Lead Product(s): Certepetide,Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Peptide, Unconjugated
Sponsor: Lisata Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 06, 2024
Lead Product(s) : Certepetide,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Lisata Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration
Details : The collaboration aims to investigate the benefits of combining Lisata's, LSTA1 (certepetide), with ValoTx's platform technology, PeptiCRAd, and a checkpoint inhibitor in a melanoma mouse model.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Undisclosed
November 06, 2024
Details:
PeptiCRAd-1 is an intratumoral injection vaccine, being investigated for Synovial Sarcoma treatment, in combination with Pembrolizumab and Cyclophosphamide.
Lead Product(s): PeptiCRAd-1,Cyclophosphamide,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Vaccine
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 29, 2023
Lead Product(s) : PeptiCRAd-1,Cyclophosphamide,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PeptiCRAd-1 is an intratumoral injection vaccine, being investigated for Synovial Sarcoma treatment, in combination with Pembrolizumab and Cyclophosphamide.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
November 29, 2023
Details:
The collaboration aims to investigate immune responses to PeptiCRAd-1 in its Phase 1 clinical study. PeptiCRAd-1 is the company’s lead product made up of its virus VALO-D102 coated with MAGE-A3 and NY-ESO-1 peptides.
Lead Product(s): PeptiCRAd-1,Cyclophosphamide,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Vaccine
Sponsor: Texcell
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 13, 2023
Lead Product(s) : PeptiCRAd-1,Cyclophosphamide,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Texcell
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to investigate immune responses to PeptiCRAd-1 in its Phase 1 clinical study. PeptiCRAd-1 is the company’s lead product made up of its virus VALO-D102 coated with MAGE-A3 and NY-ESO-1 peptides.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
June 13, 2023
Details:
PeptiCRAd-1 is a cancer immunotherapy drug candidate designed to stimulate systemic tumor-directed cytotoxic T-cell responses in cancer patients. Combined with its local immune modulation effect at the tumor site, it has the potential to deliver synergistic clinical outcomes.
Lead Product(s): PeptiCRAd-1,Cyclophosphamide,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Vaccine
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 23, 2023
Lead Product(s) : PeptiCRAd-1,Cyclophosphamide,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Valo Therapeutics Announces First Patient Dosed with PeptiCRAd-1 - Innovative Immuno-oncology
Details : PeptiCRAd-1 is a cancer immunotherapy drug candidate designed to stimulate systemic tumor-directed cytotoxic T-cell responses in cancer patients. Combined with its local immune modulation effect at the tumor site, it has the potential to deliver synergis...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
May 23, 2023
Details:
PeptiCRAd-1 is a cancer immunotherapy drug candidate designed to stimulate systemic tumor-directed cytotoxic T-cell responses in cancer patients. Combined with its local immune modulation effect at the tumor site, it has the potential to deliver synergistic clinical outcomes.
Lead Product(s): PeptiCRAd-1,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Vaccine
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 16, 2023
Lead Product(s) : PeptiCRAd-1,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PeptiCRAd-1 is a cancer immunotherapy drug candidate designed to stimulate systemic tumor-directed cytotoxic T-cell responses in cancer patients. Combined with its local immune modulation effect at the tumor site, it has the potential to deliver synergis...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
February 16, 2023
Details:
VALO-D102 is a fundamental component of the company’s proprietary PeptiCRAd (peptide-coated Conditionally Replicating Adenovirus) immuno-oncology platform. PeptiCRAd combines two cancer immunotherapy approaches: an oncolytic Adenovirus and a peptide vaccine.
Lead Product(s): PeptiCRAd-1
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Vaccine
Sponsor: Exothera
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 11, 2023
Valo Therapeutics Selects Exothera to Develop Large-Scale Oncolytic Adenovirus Manufacturing
Details : VALO-D102 is a fundamental component of the company’s proprietary PeptiCRAd (peptide-coated Conditionally Replicating Adenovirus) immuno-oncology platform. PeptiCRAd combines two cancer immunotherapy approaches: an oncolytic Adenovirus and a peptide va...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
January 11, 2023
Details:
PeptiCRAd-1 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Melanoma.
Lead Product(s): PeptiCRAd-1,Cyclophosphamide,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Vaccine
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 08, 2022
Lead Product(s) : PeptiCRAd-1,Cyclophosphamide,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Details : PeptiCRAd-1 is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Melanoma.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
August 08, 2022
Details:
PeptiCHIP enables to identify antigens faster than existing technologies and, in combination with lead delivery platform, PeptiCRAd (unique way of combining two clinically proven cancer immunotherapy approaches: an oncolytic Adenovirus and a peptide vaccine).
Lead Product(s): PeptiCRAd
Therapeutic Area: Oncology Brand Name: PeptiCRAd
Study Phase: DiscoveryProduct Type: Vaccine
Recipient: University of Helsinki
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 26, 2022
Details : PeptiCHIP enables to identify antigens faster than existing technologies and, in combination with lead delivery platform, PeptiCRAd (unique way of combining two clinically proven cancer immunotherapy approaches: an oncolytic Adenovirus and a peptide vacc...
Product Name : PeptiCRAd
Product Type : Vaccine
Upfront Cash : Undisclosed
July 26, 2022
Details:
In immunological tumour animal models, pre-immunisation with tetanus specific peptides significantly enhanced responses following subsequent vaccination with tumour-peptide coated oncolytic Adenoviruses; ValoTx’s PeptiCRAd technology, in combination with anti-PD1.
Lead Product(s): PeptiCRAd-1
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Vaccine
Recipient: University of Helsinki
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 06, 2022
Lead Product(s) : PeptiCRAd-1
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : University of Helsinki
Deal Size : Undisclosed
Deal Type : Acquisition
Valo Therapeutics Acquires University of Helsinki´s Technology that Capitalizes on Pre-Existing I...
Details : In immunological tumour animal models, pre-immunisation with tetanus specific peptides significantly enhanced responses following subsequent vaccination with tumour-peptide coated oncolytic Adenoviruses; ValoTx’s PeptiCRAd technology, in combination wi...
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
January 06, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
